what's VitaDAO?
VitaDAO is a decentralized autonomous organization (DAO) that operates as a community-owned collective dedicated to funding and advancing early-stage longevity science research. By leveraging blockchain technology, it enables token holders to participate in governance decisions, such as voting on research proposals and allocating funds to promising projects in areas like aging biology and healthspan extension. This model democratizes scientific funding, allowing global contributors to support innovative research that might otherwise face barriers in traditional biotech financing. The DAO's governance token, VITA, powers its ecosystem, facilitating community-driven initiatives including the incubation of biotech spinouts and partnerships with AI tools for hypothesis generation. VitaDAO has bridged its operations to networks like Solana to enhance scalability and efficiency in funding mechanisms, such as on-chain auctions and liquidity pools for research-focused tokens. It emphasizes transparency, with all funded projects' progress tracked publicly on the blockchain. Through collaborations in the DeSci space, VitaDAO fosters an open-source approach to longevity research, integrating elements like agentic AI co-scientists and multi-chain liquidity to accelerate discoveries. This positions it as a pioneer in using Web3 to bridge the gap between scientific innovation and community investment.
$VITA token bridged to Solana for faster decentralized funding and multichain access, while the VitaDAO ecosystem expands with new IP primitives (Commons IPT), research tokens ($FIDEL for Alzheimer's, $LSD and $PSILO for psychedelics), and BioAgent Aubrai launching with BioProtocol partnership.
contract
ethereum
solana
base
Deployed Labs beta public view for tracking project progress, managing research operations, and monitoring key milestones.
VitaFast Bio and VitaRNA Bio are in talks with a major government for longevity clinical trials.
VitaDAO-backed Fox03 project goes live on Molecule platform, developing RNA therapeutic targeting the longevity-linked FOXO3 gene for degenerative disc disease treatment.
$VITA token has been bridged to Solana to enable faster decentralized funding and multichain access.
VitaDAO team members are launching Commons IPT, a new open IP primitive on BioProtocol, with the first commons IP token designated for DMT research funding.
New Alzheimer's research token $FIDEL launches on Molecule with support from multiple DeSci organizations.
New psychedelic-focused tokens $LSD and $PSILO launching on Pump Science platform, expanding research scope to include psychedelics as longevity molecules.
First BioAgent Aubrai launches with BioProtocol partnership, implementing onchain idea registration via Molecule's Protocol.
24-hour Aubrai token sale launches with $269K FDV, 0.5% max allocation per user, and post-listing value of $896K on AMM.
Two research projects (VITARNA and VITA-FAST) advance to human trials phase, marking transition from theoretical to practical development.
$45M AUM achieved in 9 months with planned integration of IPT launch mechanics and new partnerships with Solana, Base, and Protocol Labs for decentralized scientific agent stack development. Team announces plans to revest May token unlock.
$45M AUM achieved in 9 months with major partnerships established; team proposes extending token unlock period beyond May.